Vanda board rejects conditional resignation of director Chrousos after less-than-majority vote

Vanda Pharmaceuticals Inc.

Director Phaedra S. Chrousos received less than majority votes at 2024 annual meeting, tendered conditional resignation.
Board (excluding Chrousos) unanimously voted May 22, 2024 to reject resignation, citing qualifications and proxy advisory firm's recommendation related to Rights Agreement.
Chrousos will continue as director until Vanda's 2027 annual meeting or until successor elected.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.